Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02991222 · ClinicalTrials.gov registry record · Phase 1
Bioavailability Study of SPARC001(Study 1) in Healthy Adult Volunteers
A Phase 1 study, sponsored by Sun Pharma Advanced Research Company Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02991222: Completed Phase 1 study, sponsored by Sun Pharma Advanced Research Company Limited.
NCT02991222 is a Phase 1 study that has completed, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02991222, a Phase 1 study, has completed, sponsored by Sun Pharma Advanced Research Company Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The objective of the study is to determine the relative bioavailability, safety and tolerability of SPARC001 and Reference001 in healthy, adult, male and female subjects
Interventions
- DRUG SPARC001 type I
- DRUG SPARC001 type II
- DRUG Reference001 type I
- DRUG Reference001 type II
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-01-15 |
| Est. Completion | 2017-04 |
| Phase | Phase 1 |
What the finished NCT02991222 record still lists
NCT02991222 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 4 interventions - of which SPARC001 type I is the first listed.
NCT02991222 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02991222 about?
NCT02991222 is a clinical study titled "Bioavailability Study of SPARC001(Study 1) in Healthy Adult Volunteers". The objective of the study is to determine the relative bioavailability, safety and tolerability of SPARC001 and Reference001 in healthy, adult, male and female subjects
What is the current status of trial NCT02991222?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2017-01-15. Estimated completion is 2017-04.
What interventions are being tested in trial NCT02991222?
The interventions under investigation include: SPARC001 type I (DRUG), SPARC001 type II (DRUG), Reference001 type I (DRUG), Reference001 type II (DRUG).
Who is sponsoring clinical trial NCT02991222?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02991222's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI